<DOC>
	<DOCNO>NCT00600977</DOCNO>
	<brief_summary>Phase II multicentric study compare VAD regimen continuous infusion 96 hour doxorubicin , vincristine dexamethasone 90 minute infusion equivalent dos Dox li-PEG , bolus infusion vincristine dexamethasone</brief_summary>
	<brief_title>Liposomal Anthracyclin Treatment Elderly ALL</brief_title>
	<detailed_description>Patients age 55 year assess response steroid day -7 day 0 During steroid therapy , Ph status determinated : patient Ph+ ALL treat accord another French Protocol patient Ph-ve ALL include `` caelyx '' protocol randomly allocate induction VAD vadox-li-Peg ( caelyx ) . A second course induction therapy VAD+ cyclophosphamide Vadox-li-peg+ cyclophosphamide ( accord initial randomization arm ) give patient . Consolidation therapy include 2 course vad vadox-li-Peg , accord initial random allocation , follow two course cytarabine , cyclophosphamide thioguanine . During induction consolidation therapy , doxorubicin liposomal pegylated doxorubicin pharmacokinetics assess patient . Treatment occult CNS invasion include skull radiotherapy 6 intrathecal injection ( stero√èds+methotrexate ) A two year maintenance course 6 mercaptopurine methotrexate offer patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>55 year age old ECOG performance &lt; /=2 &gt; /=3 VIH negative Absence previous ALL treatment Informed consent sign SGPT Bilirubin &lt; 4x upper limit normal Normal creatinine age cardiac state compatible anthacyclin ALL Philadelphia Chromosome ALL3 CML blast crisis Cardiac insufficiency and/ leave ventricular ejection fraction &lt; 50 % Evolutive infection Presence evolutifs cancer ongoing treatment mental status incompatible inform consent</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>ALL</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Pharmacokinetics doxorubicin ( pegylated )</keyword>
	<keyword>elderly ALL</keyword>
</DOC>